Interim results from a large multinational extension trial (guardian™2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. (13th June 2016) - Lentz, S. R.; Cerqueira, M.; Janic, D.; Kempton, C.; Matytsina, I.; Misgav, M.; Oldenburg, J.; Ozelo, M.; Recht, M.; Rosholm, A.; Savic, A.; Suzuki, T.; et al.